- Home
- LOCO vs NNNN Comparison
LOCO vs NNNN Comparison
Compare LOCO & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- NNNN
- Stock Information
- Founded
- LOCO 1980
- NNNN 2021
- Country
- LOCO United States
- NNNN Germany
- Employees
- LOCO N/A
- NNNN N/A
- Industry
- LOCO Restaurants
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LOCO Consumer Discretionary
- NNNN Health Care
- Exchange
- LOCO Nasdaq
- NNNN Nasdaq
- Market Cap
- LOCO 331.5M
- NNNN 369.6M
- IPO Year
- LOCO 2014
- NNNN 2025
- Fundamental
- Price
- LOCO $10.96
- NNNN $49.26
- Analyst Decision
- LOCO Buy
- NNNN
- Analyst Count
- LOCO 3
- NNNN 0
- Target Price
- LOCO $15.50
- NNNN N/A
- AVG Volume (30 Days)
- LOCO 347.2K
- NNNN 220.1K
- Earning Date
- LOCO 07-31-2025
- NNNN 01-01-0001
- Dividend Yield
- LOCO N/A
- NNNN N/A
- EPS Growth
- LOCO 6.54
- NNNN N/A
- EPS
- LOCO 0.86
- NNNN 0.06
- Revenue
- LOCO $476,032,000.00
- NNNN $8,185,146.00
- Revenue This Year
- LOCO $6.28
- NNNN N/A
- Revenue Next Year
- LOCO $1.14
- NNNN N/A
- P/E Ratio
- LOCO $12.99
- NNNN $908.77
- Revenue Growth
- LOCO 1.22
- NNNN 21.95
- 52 Week Low
- LOCO $8.29
- NNNN $5.18
- 52 Week High
- LOCO $14.25
- NNNN $53.11
- Technical
- Relative Strength Index (RSI)
- LOCO 57.24
- NNNN N/A
- Support Level
- LOCO $10.94
- NNNN N/A
- Resistance Level
- LOCO $11.55
- NNNN N/A
- Average True Range (ATR)
- LOCO 0.40
- NNNN 0.00
- MACD
- LOCO -0.02
- NNNN 0.00
- Stochastic Oscillator
- LOCO 67.74
- NNNN 0.00
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.